Genetic markers for CDK4/6 inhibitor therapy in breast cancer
Part of Cancer, Skin clinical trials.
This trial looks at how genetic markers and other substances in your blood might help personalize treatment with CDK4/6 inhibitors, a targeted therapy for breast cancer. It aims to find better ways to predict which patients will benefit most.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman.
- You must have a breast cancer diagnosis.
- You must be 18 years old or older.
- Your doctor has recommended a CDK4/6 inhibitor (a type of targeted therapy) for your treatment.
- You are comfortable communicating in English.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how gut bacteria affect response to a type of targeted therapy (CDK4/6 inhibitors) combined with hormone therapy in breast cancer that is hormone receptor-positive and HER2-negative. It may help find out why some people respond better to treatment and could lead to better personalized care.
This study looks at how well CDK4/6 inhibitors (a type of targeted therapy) work in real-world patients with HR+/HER2- advanced breast cancer. By collecting medical data from people treated at this hospital, doctors hope to learn more about the effectiveness and safety of these drugs in everyday practice.
This trial studies how CDK4/6 medicines fit into treatment for people with advanced hormone receptor–positive breast cancer that cannot be cured with surgery or radiation. It may help doctors understand the best way to use these medicines for disease that has returned or spread.
This trial tests whether a CDK4/6 inhibitor given after surgery can help prevent breast cancer from coming back. It is for people with HR-positive, HER2-negative breast cancer that has not spread to other parts of the body.
This study looks at how well CDK4/6 inhibitors combined with hormone therapy work in real-world settings for people with a certain type of advanced breast cancer (HR+/HER2-). It aims to understand the best treatment path and what happens next.
This study looks at how well CDK4/6 inhibitors work in older adults with breast cancer who are taking these drugs after surgery to help prevent the cancer from coming back. It will follow patients over time to learn more about their experiences.
Hear when a new CDK4/6 Inhibitor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.